I heart injections: scPharmaceuticals files for a $100 million IPO

Shutterstock photo

scPharmaceuticals, which is commercializing injectable version of an intravenous drug for heart failure, filed on Monday with the SEC to raise up to $100 million in an initial public offering.

The Burlington, MA-based company was founded in 2013 and plans to list on the Nasdaq under the symbol SCPH. scPharmaceuticals filed confidentially on August 31, 2017. Jefferies, Leerink Partners and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.

The article I heart injections: scPharmaceuticals files for a $100 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?